CD20 positive

CD68, CD206, PD-L1, and LOXL3 may collaboratively contribute to the regulation of the PM microenvironment and are closely linked to the invasion and metastasis of PM. Therefore, LOXL3 can be used as both a prognostic marker and a potential therapeutic target for PM.

This study presents flow cytometry-based assessment of Rituximab efficacy in Libyan B cell lymphoma patients, providing novel population-specific data.

FCM yields reliable diagnostic information within hours of tissue collection and supports early therapeutic decisions in PCNSL. Discordant results may reflect reactive T-cell infiltration. This is the first study to present detailed subset analyses in PCNSL using FCM in correlation with pathology, underscoring its utility as a rapid diagnostic tool.

HFD induces microbiota-directed metabolic reprogramming and M2 polarization, synergistically accelerating CRC. Notably, targeting key pro-inflammatory taxa (e.g., B. massiliensis) or glycan hydrolysis pathways (e.g. GH95 enzyme) may provide mechanism-guided anti-CRC strategies.

In patients with benign prostate hyperplasia, proliferative blood vessels are found in the interstitium, and there is an accumulation of proliferative large cells in the lumen, which do not resemble endothelial cells, epithelial cells, tissue cells, or inflammatory cells. Pathologists should consider the possibility of intravascular large B-cell lymphoma and conduct immunohistochemical staining for large B-cell lymphoma. Primary intravascular large B-cell lymphoma of the prostate should be diagnosed after ruling out metastatic tumors.

The simultaneous inversion of the IL-10/IL-6 ratio with edema onset suggests a cytokine shift unmasking an inflammatory response previously suppressed by malignant lymphoproliferation. This pattern supports an immune reconstitution inflammatory syndrome-like mechanism as the most likely cause.

The patient underwent four cycles of R-CHOP chemotherapy...Early tissue biopsy and immunohistochemistry are critical to avoid prolonged misdiagnosis and inappropriate therapy. Clinicians should maintain a high index of suspicion for malignancy in non-resolving bone lesions.

The patient received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy with intrathecal methotrexate. This case underscores the importance of including PCL in the differential diagnosis of right atrial masses. Early imaging, prompt tissue diagnosis, and chemotherapy can lead to excellent outcomes even in aggressive disease presentations.

Fluorescence in situ hybridization (FISH) revealed a chromosomal translocation, t(14;18). These findings supported a diagnosis of ISFN.

Hematoxylin-eosin staining combined with immunohistochemistry (CD1a, S100, CD207) is essential for definitive diagnosis. LCH should be differentiated from hepatic parasitic infections, primary SC, EBV+ IFDCS, and IMT.

To conduct a cost-effectiveness analysis comparing zuberitamab combined with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab combined with CHOP (R-CHOP) as first-line therapy for previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) patients in China. The cost-effectiveness acceptability curve (CEAC) demonstrated R-CHOP's superior cost-effectiveness probability relative to Hi-CHOP across a WTP range from $0 to $150,000. Given that Hi-CHOP is not cost-effective at conventional WTP thresholds, a substantial price reduction or unnecessary procedures, and optimizing clinical workflows for Hi-CHOP would be necessary to make it an economically viable first-line option for DLBCL compared to R-CHOP.

P2, N=46, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2024 --> Sep 2026